SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases ...
Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...
Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) ...
We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...
SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been making significant strides in its commercial and ...
SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been making significant strides in its commercial and ...
Springworks Therapeutics (SWTX – Research Report) received a Buy rating and a $60.00 price target from Evercore ISI analyst Cory Kasimov today.
(MENAFN- GlobeNewsWire - Nasdaq) STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage ...